FDA Approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012

JAMA

Volumn 311, Issue 4, 2014, Pages 385-391

  Rome, Benjamin N ^a,b   Kramer, Daniel B ^a,b,c,d   Kesselheim, Aaron S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Hebrew Seniorlife's Res Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892748062     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.284986     Document Type: Article

References (25)

1. Premarket approval (PMA). US Food and Drug Administration. http://www.fda.gov /medicaldevices/deviceregulationandguidance /howtomarketyourdevice/premarketsubmissions /premarketapprovalpma/. Accessed December 26, 2013.
2. Medical Device Amendments of 1976 [Pub L No. 94-295]. US Government Printing Office. http://www.gpo.gov/fdsys/pkg/STATUTE-90/pdf /STATUTE-90-Pg539.pdf. Accessed December 26, 2013.
3. Hauser RG, Almquist AK. Learning from our mistakes? testing new ICD technology. N Engl J Med. 2008;359(24):2517-2519.
4. Kay GN, Ellenbogen KA. An ICD lead advisory: a plea for more diligence and more data. Pacing Clin Electrophysiol. 2012;35(6):648-649.
5. Premarket approval (PMA) database. US Food and Drug Administration. http://www.accessdata\.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm. Accessed January 4, 2013.
6. Crosse MG. Medical devices: shortcomings in FDA's premarket review, postmarket surveillance, and inspections of device manufacturing establishments. US Government Accountability Office. http://www.gao.gov/products/GAO-09-370T. Accessed December 26, 2013.
7. Guidance for industry and FDA staff: modifications to devices subject to premarket approval (PMA): the PMA supplement decision-making process [2008]. US Dept of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. http://www.fda.gov/downloads /MedicalDevices/DeviceRegulationandGuidance /GuidanceDocuments/UCM089360.pdf. Accessed December 26, 2013.
8. The least burdensome provisions of the FDA Modernization Act of 1997: concept and principles: final guidance for FDA and industry. US Dept of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation, Center for Biologics Evaluation and Research. http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance /GuidanceDocuments/ucm085994.htm. Accessed December 26, 2013.
9. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med. 2003;349(19):1836-1847.
10. Product classification. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm. Accessed January 20, 2013.
11. Safe Medical Devices Act of 1990 [Pub L No. 101-629]. US Government Printing Office. http://www.gpo.gov/fdsys/pkg/STATUTE-104/pdf/STATUTE-104- Pg4511.pdf. Accessed December 26, 2013.
12. "Real-time" review program for premarket approval application (PMA) supplements. US Food and Drug Administration, Office of Device Evaluation; 1997.
13. Medical Device User Fee and Modernization Act of 2002 [Pub L No. 107-250]. US Government Printing Office. http://www.gpo.gov/fdsys/pkg/PLAW- 107publ250/content-detail.html. Accessed December 26, 2013.
14. PMA review fees. US Food and Drug Administration. http://www.fda.gov /MedicalDevices/DeviceRegulationandGuidance /HowtoMarketYourDevice/ PremarketSubmissions /PremarketApprovalPMA/ucm048161.htm. Accessed October 26, 2013.
15. Guidance for industry and FDA staff: bundling multiple devices or multiple indications in a single submission. US Dept of Health and Human Services, Center for Devices and Radiological Health; 2003.
16. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009;302(24):2679-2685.
17. Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010;17(1):2-7.
18. Chen CE, Dhruva SS, Redberg RF. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval. JAMA. 2012;308(17):1740-1742.
19. Shein MJ, Schultz DG. Testing new ICD technology. N Engl J Med. 2008;359(24):2610.
20. Lampert R,Wang Y, Curtis JP. Variation among hospitals in selection of higher-cost, "higher-tech," implantable cardioverter-defibrillators: data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. Am Heart J. 2013;165(6):1015-1023.
21. Premarket approval (PMA) database: 2012;S176:010031. US Food and Drug Administration. http://www.accessdata.fda.gov /scripts/cdrh/cfdocs/cfpma/pma. cfm?id=26238. Accessed December 27, 2013.
22. Medical devices and the public's health: the 510(k) clearance process at 35 years. Institute of Medicine. http://www.iom.edu/Reports/2011 /Medical-Devices-and-the-Publics-Health-The-FDA -510k-Clearance-Process-at-35- Years.aspx. Accessed December 26, 2013.
23. Zuckerman DM, Brown P, Nissen SE. Medical device recalls and the FDA approval process. Arch Intern Med. 2011;171(11):1006-1011.
24. Ardaugh BM, Graves SE, Redberg RF. The 510(k) ancestry of ametal-on-metal hip implant. N Engl J Med. 2013;368(2):97-100.
25. Food and Drug Administration, HHS. Unique device identification system: final rule. Fed Regist. 2013;78(185):58785-58828.